Xenon Pharmaceuticals Inc. (XENE)
- GlobeNewswire
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
Company Presents Additional Positive Data from Open Label Extension of Phase 2b ‘X-TOLE’ Clinical Trial for Focal Onset Seizures XEN1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking Place on Sunday, December 4, 2022 BURNABY, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American E
- GlobeNewswire
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
BURNABY, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the Bank of America Securities Biotech SMID Cap Conference 2022 taking place virtually from December 7-8, 2022. Fireside Chat/Company Presentation Details: Date:Wednesday, December 7, 2022Time:1:10 pm Eastern Time (10:10 am Pacific T
- Simply Wall St.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Analysts Just Trimmed Their Revenue Forecasts By 10%
Market forces rained on the parade of Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) shareholders today, when the analysts...
